Merck & Co., Inc. (MRK)
Merck Q3 financial results top estimates, company lowers revenue guidance
Merck & Co Inc (NYSE:MRK, ETR:6MK) on Thursday reported third quarter 2025 earnings and revenue that surpassed Wall Street expectations, lifted by strong demand for its cancer immunotherapy Keytruda, but reduced its full-year sales outlook to reflect lower estimated tariff costs, among other factors. The pharmaceutical company's revenue for the quarter rose 4% year over year to $17.28 billion, exceeding the $16.96 billion analyst consensus estimate provided by LSEG.
Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
Merck (MRK) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $1.57 per share a year ago.
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower estimated tariff costs and other items. Sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago.
Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil
Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
Merck breaks ground on $3B manufacturing plant in Virginia
Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
Trump strikes deal with Merck to cut IVF drug prices in return for tariff relief
President Donald Trump has unveiled an agreement with Germany's Merck KGaA to lower the cost of its fertility medicines in the United States in exchange for exemptions from threatened tariffs, part of his drive to make in vitro fertilisation (IVF) more affordable. Under the deal, Merck will sell its full range of IVF drugs through Trump's direct-to-consumer platform, TrumpRX, and expand manufacturing in the US.
Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room
Merck & Co., Inc. remains the largest U.S. pharma company in 2025, driven by oncology and Keytruda, despite looming patent expiration risks. Keytruda accounts for over half of MRK's pharmaceutical revenue, making its 2028 patent loss a significant challenge for future growth. MRK management is actively working to offset the Keytruda revenue gap, laying a foundation for post-2028 recovery.
